In the study of human neurodegenerative diseases—both common conditions such as Alzheimer’s and Parkinson’s disease, and relatively rarer ones such as amyotrophic lateral sclerosis (ALS) and Huntington’s disease—gene-expression analysis is revealing new, and sometimes shared, pathways of disease. For example, over the past several years, gene expression studies have implicated biological pathways such as inflammation, protein homeostasis, and RNA splicing as critical to the development and progression of multiple neurodegenerative disorders.

Recently, gene-expression research has also suggested a pan-neurodegenerative disease response that is shared in Huntington’s disease (HD) and Parkinson’s disease (PD). Although the two disorders are both characterized by aberrant protein aggregation in the brain, the specific proteins that aggregate and types of neurons affected differ; but research from Boston University’s Bioinformatics Hub, published in Frontiers in Molecular Neuroscience in January 2018, demonstrates that there is surprising consistency between the two disorders in enriched biological pathways, implicating common biological processes of neuroinflammation, apoptosis, transcriptional dysregulation, and neuron-associated functions.

“Comparison of the differentially expressed (DE) genes highlights a set of consistently altered genes that span both diseases,” wrote lead author Adam Labadorf, Ph.D., founder and director of the Bioinformatics Hub. “In particular, processes involving key genes in both the innate and adaptive immune response are the most prominent among genes implicated in both HD and PD.”

But although both disorders had comparable numbers of DE genes, there were key differences. “DE genes unique to HD are enriched in far more coherent biological processes than the DE genes unique to PD, suggesting that PD may represent a more heterogeneous disorder,” Dr. Labadorf wrote.

The new research was made possible by high-throughput RNA sequencing technology, Dr. Labadorf told Biocompare. “Looking at the more than 25,000 genes in samples of diseased brain tissue at once is a challenging task, to say the least,” he said. “RNA sequencing allows us to quantify the relative number of RNA molecules for most of the genes in a genome at once. It is unbiased in the sense that in contrast to older gene-expresion technologies, it is possible to detect any RNA molecule that exists in a sample—facilitating analysis of genes that are known, but also those that aren’t. This high-throughput sequencing technology has enabled us to measure, with high resolution, the genes that are perturbed in diseased brain tissue vs. normal. We can then organize those genes into sets of higher level biological functions because many of them have been previously studied, categorized, and annotated by other investigators.”

Single-cell interrogation

The next frontier is the expansion of this sequencing technology into single-cell interrogation. “Single-cell sequencing technology is a new set of protocols wherein individual cells can be isolated, and RNA/DNA can be extracted, barcoded, and separated during analysis,” explained Dr. Labadorf. “The advantages of this compared with bulk RNA sequencing—in which you take complex tissue and essentially put it in a blender—are obvious. Bulk sequencing makes it difficult to identify which gene-expression differences originate from specifici cell types. For instance, it may be clinically or theapeutically important that a given gene is expressed differently specifically in neurons, and not in astrocytes, oligodendrocytes, or microglia. This is particularly true in neurodegeneration, where the specific types and locations of neurons that are the most vulnerable vary widely between different diseases. Single-cell technology will give us more insight into which cells are perturbed in which ways.”

A leader in single-cell gene-expression research in neurodegenerative disease is Philip De Jager, M.D., Chief of the Division of Neuro-Immunology and Weil-Granat professor of Neurology at Columbia University Irving Medical Center. Dr. De Jager recently began a study designed to create a reference map of single-cell transcriptomes from the aging human brain’s frontal cortex and white matter.

“We’ve spent a lot of time on single-cell nucleus sequencing from frozen brain material, which helps to enumerate all of the cells found in the older brain and to see which ones might be changing,” said Dr. De Jager. “About half of the amount of cognitive decline in all forms of aging-related dementia remains unexplained by known biology such as tau and amyloid. To find the molecular pathways related to the unknown component of clinical dementia, we needed to plan ahead—to design studies that measure how well the person was functioning before death. With frozen brain tissue that has come in randomly from the community, that information is often relatively sparse.”

Dementia studies

So he is collaborating with David Bennett, M.D., director of the Rush Alzheimer’s Disease Center at Rush University Medical Center and the Robert C. Borwell Professor of Neurological Science in the Department of Neurological Sciences at Rush Medical College, who leads two of the largest dementia studies currently underway in the United States. Dr. Bennett has enrolled some 3,500 older people into two ongoing studies—the Religious Orders Study, which examines memory loss in nuns, brothers, and priests from across the United States, and the Rush Memory and Aging Project, a similar study of laypersons in northeastern Illinois.

“After death, a detailed pathological exam is performed, which gives us a sense of how the person’s cognitive performance compares to the amount of pathology found,” explained Dr. De Jager. “Is this person performing better or worse based on the known pathology?”

So far, he and his team have done single-nucleus sequencing on 24 postmortem brain samples from these cohorts. “That’s actually a moderately large sample for this type of work, but to do powerful statistical analyses, we need approximately 500 samples, which we will have by the end of next year,” Dr. De Jager added.

Other new techniques are being developed to facilitate single-cell gene expression studies in neurodegenerative disease. “The postmortem human brain typically needs to have been flash frozen, and frozen tissue does not dissociate very well, especially such complex tissue as the human brain,” said Dr. Labadorf. “One of my collaborators is working on a technique to extract whole cells from frozen brain tissue, which enables us to overcome some of the difficulties involved in single-nuclear RNA sequencing.